Table 4.
Skin Sensitization Potency for Local Lymph Node Assay and Nonanimal Methods
| Chemical | Approach 1 LLNA EC3 (%) | Approach 2 mean LLNA EC3 (%) | DPRA Avg.Lys.Cys (% depletion)a | KeratinoSens EC1.5 (μM) | h-CLAT minimum induction threshold (μg/mL)b |
|---|---|---|---|---|---|
| DCOIT | 0.004 | 0.008 | 55.2 | 1.32 | 0.92 |
| CMIT/MIT | 0.002 | 0.018 | 55.3 | 3.41 | 2.63 |
| OIT | 0.2–0.25 | 0.361 | 50 | 2.19 | 0.95 |
| MIT | 0.863 | 1.154 | 50 | 9.54 | 11.6 |
| BIT | 1.54 | 10.57 | NA c | 3.14 | 7.63 |
| BBIT | NA | NA | 50 | 3.84 | 3.01 |
Bold values refers to GHS 1A (or strong) for LLNA and h-CLAT or high reactivity for DPRA; italicized values refer to GHS 1B for LLNA or weak for h-CLAT; bold and italicized values refer to all KeratinoSens tests that met the criteria for a positive response, but potency categorization was not possible.
a
Reactivity classes based on OECD Test Guideline 442C.9
b
Potency categories based on Takenouchi et al.23
c
Cysteine peptide depletion was 100%, but lysine peptide depletion could not be evaluated because the test substance co-eluted with the lysine peptide peak.
DPRA, direct peptide reactivity assay; h-CLAT, human cell line activation test; NA, not available.